12 week, comparing safety of HMR1964 and insulin aspart used in continuous subcutaneous infusion in type 1 diabetes

Trial Profile

12 week, comparing safety of HMR1964 and insulin aspart used in continuous subcutaneous infusion in type 1 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2006

At a glance

  • Drugs Insulin aspart; Insulin glulisine
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Aventis Pharmaceuticals
  • Most Recent Events

    • 15 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top